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ABSTRACT
Background Clinical classiﬁcation of rare sequence
changes identiﬁed in the breast cancer susceptibility
genes BRCA1 and BRCA2 is essential for appropriate
genetic counselling of individuals carrying these variants.
We previously showed that variant BRCA1 c.5096G>A p.
Arg1699Gln in the BRCA1 transcriptional transactivation
domain demonstrated equivocal results from a series
of functional assays, and proposed that this variant
may confer low to moderate risk of cancer.
Methods Measures of genetic risk (report of family
history, segregation) were assessed for 68 BRCA1
c.5096G>A p.Arg1699Gln (R1699Q) families recruited
through family cancer clinics, comparing results with
34 families carrying the previously classiﬁed pathogenic
BRCA1 c.5095C>T p.Arg1699Trp (R1699W) mutation at
the same residue, and to 243 breast cancer families with
no BRCA1 pathogenic mutation (BRCA-X).
Results Comparison of BRCA1 carrier prediction scores
of probands using the BOADICEA risk prediction tool
revealed that BRCA1 c.5096G>A p.Arg1699Gln variant
carriers had family histories that were less ‘BRCA1-like’
than BRCA1 c.5095C>T p.Arg1699Trp mutation carriers
(p<0.00001), but more ‘BRCA1-like’ than BRCA-X
families (p=0.0004). Further, modiﬁed segregation
analysis of the subset of 30 families with additional
genotyping showed that BRCA1 c.5096G >A p.
Arg1699Gln had reduced penetrance compared with the
average truncating BRCA1 mutation penetrance
(p=0.0002), with estimated cumulative risks to age 70
of breast or ovarian cancer of 24%.
Conclusions Our results provide substantial evidence
that the BRCA1 c.5096G>A p.Arg1699Gln (R1699Q)
variant, demonstrating ambiguous functional deﬁciency
across multiple assays, is associated with
intermediate risk of breast and ovarian cancer,
highlighting challenges for risk modelling and clinical
management of patients of this and other potential
moderate-risk variants.
INTRODUCTION
The clinical classiﬁcation of rare sequence changes
identiﬁed in the high-risk breast cancer susceptibil-
ity genes BRCA1 and BRCA2 is essential for appro-
priate genetic counselling of individuals carrying
these variants. Classiﬁcation of BRCA1 and BRCA2
variants was facilitated by the development of a
multifactorial likelihood model,1 which provides a
quantitative estimate of pathogenicity by assessing
measures of genetic and other features of variant
carriers relative to characteristics observed for clas-
sical high-risk mutations. Moreover, this quantita-
tive assessment of risk has been linked to clinical
management guidelines to provide a basis for stan-
dardised variant reporting, variant classiﬁcation
and management of families with such variants.2
The multifactorial likelihood methodology has
been applied in multiple studies,1 3–15 with more
than 200 BRCA1 or BRCA2 variants now classiﬁed
using this approach.16 However, the multifactorial
approach is designed to distinguish high-risk muta-
tions from variants with no or little clinical signiﬁ-
cance, and it is likely that additional methods are
required to detect and validate BRCA1 or BRCA2
rare variants associated with more modest risks
than the average penetrance reported for classical
mutations in these genes, that is, 65% risk of
breast cancer and 39% risk of ovarian cancer to age
70 years for BRCA1 mutations, and 45% risk of
breast cancer and 11% risk of ovarian cancer to age
70 years for BRCA2 mutations.17
We previously showed that the variant BRCA1
R1699Q (c.5096G>A p.Arg1699Gln) located in the
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BRCA1 carboxyl terminal (BRCT) regions of the transcriptional
transactivation domain (TAD) demonstrated equivocal results
from a series of functional assays, when compared with wild-
type control and known pathogenic missense mutation BRCA1
A1708E (c.5123C>A p.Ala1708Glu) which was null in all
assays.8 In particular, this variant displayed intermediate tran-
scriptional transactivation activity in human 293T and T47D
cell lines and wild-type centrosome ampliﬁcation function, but
behaved as a deleterious mutation when assayed for formation
of nuclear foci and trypsin sensitivity. There is also inconsist-
ency in assay results from other functional studies, including
discrepancies between yeast and mammalian transcriptional
transactivation assay results in a single report,18 and categorisa-
tion of R1699Q as a variant with strong functional effect due
to compromised peptide binding activity and speciﬁcity, and
compromised transcriptional activity in yet another study.19
Most recently, Chang et al20 performed an extensive study of
the R1699Q substitution using mouse embryonic stem (ES)
cell-based functional assays, and demonstrated that this variant
affected mouse ES cell survival and differentiation, and was
unable to rescue embryonic lethality of Brca1-null mice.
However, this study also demonstrated that the variant did not
cause signiﬁcant cell-cycle defects, and had no effect on
genomic stability, but it was suggested that abrogated repres-
sion of oncomir miR-155 was the underlying mechanism for
BRCA1-mediated tumour suppression. The equivocal behaviour
of this variant can be explained at a protein level, as demon-
strated by protein modelling predictions shown in
supplementary ﬁgure S1. R1699 is located in the linker connect-
ing the BRCT repeat domain, and participates in a salt bridge
between the BRCT repeats.21 The loss of salt-bridging interac-
tions and steric strain associated with accommodating a trypto-
phan substitution contributes to conformational instability of
the R1699W (c.5095C>T p.Arg1699Trp) pathogenic mutation
and, subsequently, disrupts transcriptional transactivation func-
tion. By contrast, substitutions with little or no effect on struc-
tures, such as R1699Q, may be fully or partially active in these
assays. Moreover, R1699 lies in a conserved phosphopeptide-
binding groove of the BRCA1 repeat, and plays an important
role in phosphopeptide recognition through its interaction.
Speciﬁcally, our protein modelling results directly comparing
R1699Q and R1699W show that the volume of R1699W is
likely to cause steric clashes with the phosphopeptide,
whereas, the smaller surface and volume presentation of
R1699Q will not cause steric clashes, but may modestly alter
phosphopeptide recognition (see supplementary ﬁgure S1).
These modelling predictions explain the experimental results
from biophysical assays of BACH1 binding afﬁnity which
demonstrated that R1699W leads to a signiﬁcant 160-fold
reduction in afﬁnity compared with wild-type, whereas, the
reduction is only 24-fold for R1699Q.22
We previously proposed that the R1699Q variant has partial
abrogation of BRCA1 functions, and may confer low to mod-
erate risk of cancer that would be better measured using
pooled family studies.8 In a study assessing pathogenicity of
1433 variants based on family history, co-occurrence and cose-
gregation data from a large dataset derived from clinical
testing at Myriad Genetic Laboratories, the combined odds
that BRCA1 R1699Q was a pathogenic variant compared with
neutral/no clinical signiﬁcance was 2.5:1, based on a sample of
16 family histories with cosegregation data on only three of
these.11 By contrast, BRCA1 R1699W at the same residue was
classiﬁed as pathogenic, with odds in favour of pathogenicity
of 39 978:1.11 Bioinformatic analysis shows that the arginine
at position 1699 is conserved through tunicate, but the sever-
ity of the amino acid substitution is much less marked for glu-
tamine (Grantham deviation 43) compared with tryptophan
(Grantham deviation 101). Accordingly, the Align-GVGD algo-
rithm (http://brca.iarc.fr) classiﬁes R1699Q as a C35, while
R1699W falls in the most severe C65 category for missense
alterations. Based on an analysis of the same Myriad dataset,
C35 variants were estimated to have a prior probability of
pathogenicity of 0.66, while C65 variants were associated
with a prior probability of 0.81.11 23
Mohammadi et al24 assessed the likelihood of causality by
cosegregation analysis of a single family, and reported a likeli-
hood ratio (LR) of 1.4 for R1699Q. In another genetic study of
several BRCA1/2 sequence variants, Gomez Garcia et al25 exam-
ined the R1699Q and R1699W variants as part of a model-
building exercise that incorporated family history, and esti-
mated the probability of pathogenicity to be 0.87 for R1699Q
and >0.99 for R1699W. Although this model classiﬁed both
variants as pathogenic mutations, the authors noted that
R1699Q did not cosegregate completely with disease in one of
three of the families in which such data were available.
In summary, a number of different studies to date indicate
that the R1699Q variant demonstrates inconsistent or incon-
clusive results at the functional and genetic level. In an exten-
sion of our previous study,8 we conﬁrmed the intermediate
transcriptional transactivation activity of BRCA1 R1699Q in
the 293T cell line relative to pathogenic variant R1699W at the
same residue, and then initiated large-scale genetic studies to
assess if this intermediate function might translate to the
lower risk of breast and ovarian cancer in families for R1699Q
compared with R1699W.
METHODS
Conﬁrmation of transcriptional transactivation activity
Using methods previously described,8 we ﬁrst compared tran-
scriptional transactivation activity of BRCA1 R1699Q in the
293T cell line with that of pathogenic variant, R1699W, at the
same residue, and also to pathogenic control, A1708E, and con-
ﬁrmed our original ﬁndings that this variant displayed inter-
mediate function compared with wild-type sequence and
known pathogenic TAD variants (see supplementary ﬁgure S2).
Genetic analyses
With ethical approval from the relevant institutional review
boards, we then initiated large-scale genetic studies to assess if
this intermediate function might translate to the risk of breast
and ovarian cancer in families. Informed consent was obtained
from all participants. Through collaboration facilitated in part
by the ENIGMA consortium,26 we ascertained sufﬁcient infor-
mation from multiple clinical cancer genetics centres around
the world (table 1) to compare family history and risk proﬁles
of families in which the R1699Q variant had been identiﬁed,
with families with the known pathogenic mutation R1699Wat
the same residue. For an additional reference group, we also col-
lected a set of pedigrees that had been clinically tested for
BRCA1 and BRCA2 mutations from the same centres within
the same time frame as the R1699Q and R1699W families, but
for which no pathogenic mutation or any other unclassiﬁed
variant had been found (BRCA-X). The time frame was deter-
mined by the centres to ensure that a similar criterion for
testing was used. The proband in each instance was deﬁned as
the individual initially screened for BRCA1/2 mutations.
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Family history analysis
As a measure of how each family ﬁt the characteristics of a BRCA1
mutation-positive family, we used the Breast and Ovarian Analysis
of Disease Incidence and Carrier Estimation Algorithm
(BOADICEA) risk-prediction algorithm27–30 to calculate the prob-
ability that the proband from each family was a carrier of a BRCA1
mutation based on the pedigree structure and the phenotypes of
individuals in the pedigree. BOADICEA uses a full pedigree likeli-
hood approach, and incorporates ages at diagnosis of breast and
ovarian cancer, presence of pancreatic and prostate cancer, the age
at last follow-up for unaffected individuals, and the year of birth
to account for cohort effects in penetrance. The model estimates
the simultaneous effects of the high-risk genes BRCA1 and BRCA2
using the age-speciﬁc penetrance estimates derived from 22
population-based studies,17 while allowing for unknown genetic
effects that explain the residual familial clustering of breast cancer.
The residual familial clustering is explained by a polygenic compo-
nent with variance that decreases linearly with age.
The estimated probabilities of the proband carrying a patho-
genic BRCA1 mutation based on the BOADICEA prediction
model, Bi, were then transformed in order to better ﬁt a
Gaussian distribution using a logit transformation bi= logit(Bi)
=ln(Bi/(1−Bi), so that standard statistical methods could be
used. For each centre that contributed R1699Q/W families, we
calculated the mean and SD of the probabilities calculated for
the BRCA-X families from this centre. This distribution was
used to create z-scores as Zij= (bij−Xj)/Sj, where bij is the logit
of the BOADICEA-predicted probability of a BRCA1 mutation
in the ith BRCA-X family in the jth centre, Xj and Sj are the
sample mean and SD of the logit-transformed Bi from the jth
centre. For families with the sequence variants of interest,
R1699Q and R1699W, these Zij thus represent the position of
family histories of probands carrying an R1699Q or R1699W
variant within the distribution of families tested negative for
BRCA1/2 mutations in the same centres and time frame.
Letting ZQi be the standardised logit score of the ith R1699Q
family- and ZWi represent the corresponding score for the ith
R1699W family, and assuming further that the ZQi and ZWi are
Normally distributed with means μQ and μW and variances σ2Q
and σ2W respectively, these scores can then be used to test the
following two hypotheses:
1. The family histories of R1699Q probands are more
BRCA1-like than those of matched BRCA-X. That is, we test
the null hypothesis μQ= 0 versus the alternative μQ>0 with
a one-sample t test. Rejection of the null hypothesis indi-
cates that the R1699Q families have proband/family histor-
ies more compatible with a pathogenic BRCA1 mutation
than the centre-matched BRCA-X families.
2. The family histories of R1699Q are less ‘BRCA1-like’ than
those of R1699W mutations. This is tested by a two-sample
t test of the null hypothesis μQ= μW against the one-sided
alternative μQ< μW.
If both these null hypotheses are rejected, this indicates that
R1699Q variants are, in some sense, intermediate in terms of
their BRCA1 family history proﬁle compared with BRCA-X and
BRCA1 R1699W families.
Segregation analyses
Risk was analysed more directly through analysis of cosegrega-
tion of the R1699Q/W genotypes in the relatives of probands
presenting with R1699Q/W variants.31 Analyses included 30
R1699Q informative families with 111 total tested individuals
and 19 R1699W families with 80 tested individuals. Risks were
estimated by examining the likelihood of the genotypes of the
family members (both, women affected with breast or ovarian
cancer, and healthy women) as a function of BRCA1 penetrance,
conditional on the proband’s genotype and all pedigree pheno-
types. The conditioning is needed to account for the fact that
families were ascertained on the basis of the cancer phenotypes
in the entire family, and the fact that the proband carried the
variant. In this situation, most information about penetrance
derives from the distribution of variant genotypes among
unaffected women. Because there was insufﬁcient additional
genotyping in these families to reliably estimate age-speciﬁc risk
ratios for each age group, we examined the risk associated with
the R1699Q/W variants relative to those associated with the
‘average pathogenic BRCA1 mutation’, as found in much larger
studies of predominantly truncating mutations.17 In these ana-
lyses, the age-speciﬁc HR (by decade) was assumed to be a con-
stant multiple of the estimate of Antoniou et al,17 with
cumulative penetrances re-estimated at each trial value of the
multiplier. This allowed for a similar pattern of age-speciﬁc
effects, as in BRCA1, but only required estimation of a single par-
ameter. We also repeated the analyses allowing for separate pene-
trance multipliers for breast cancer and ovarian cancer to allow
for the possibility that the functional effects of R1699Q or
R1699W might be more relevant to cancer risk for one but not
both these cancers. We varied the multiplier of the assumed
standard penetrance of BRCA1 from 0.05 to 2, in increments of
0.01, in order to ﬁnd the value that maximised the likelihood of
the observed data (and to obtain CIs). If under a particular
model, a given value of the penetrance implied risks of cancer in
carriers lower in a given age group than in non-carriers, these
were constrained to be the same as the non-carrier rates.
The analysis of penetrance was done using the LINKAGE
package of programs32 to calculate pedigree likelihoods, and the
other statistical analyses were performed using STATA V.11.0
(StatCorp, College Station, Texas, USA).
RESULTS
Table 2 shows the results of the analyses comparing family
history scores of probands from R1699Q families, R1699W
families, and families with no BRCA1 pathogenic mutation. Of
note is the ordered progression of the BOADICEA raw scores
showing clear differences between all three groups of families,















8 42 15 5 11 4
Germany 13 39 5 1 13 8
France 6 4 5 3 2 1
Spain 1 28 0 0 1 0
Denmark 2 30 10 4 0 0
Mayo clinic,
USA
1 8 7 5 0 0
Sweden 3 14 14 5 5 5
Ohio, USA 1 8 1 1 0 0
Australia 3 44 6 2 0 0
Pennsylvania,
USA
1 2 1 1 0 0
UK 4 24 4 2 2 1
South Africa 1 0 1 1 0 0
Total 243 68 30 34 19
*Number of individual clinic sites for each contributing country or region.
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and the tests of signiﬁcance between groups. The Z-scores for
R1699Q (adjusted for the mean and SD of the BRCA-X families
from the same centres) were signiﬁcantly greater than 0
(p=0.0004), indicating that carriers of the R1699Q variant
have more ‘BRCA1-like’ family histories than families that test
negative for both genes, and that they have some of the charac-
teristics of family history (eg, ovarian cancer) of BRCA1.
However, they are also clearly less ‘BRCA1-like’ than family his-
tories of probands carrying the previously classiﬁed pathogenic
R1699W mutation (p<0.00001).
Although the above analyses indicate that families carrying
R1699Q are different in terms of their personal and family
history from both BRCA-X families, and families carrying the
R1699W variant, these analyses do not directly address the
question of cancer risks conferred by these mutations. They
also do not provide a level of evidence that the variant is patho-
genic, as in the typical assessment of cosegregation within the
framework of the multifactorial model.1 33 Segregation analyses
were thus undertaken. For R1699W, the maximum likelihood
estimate of the relative proportion of the standard BRCA1 pene-
trance was 0.24 (95% CI 0.06 to 1.10), which was not signiﬁ-
cantly different from 1.0 (LR X12= 3.44; p=0.06). The odds in
favour of pathogenicity at this value of the penetrance multi-
plier were 314 100 : 1. When we allowed the possibility that
there were different multipliers for breast and ovarian cancer,
the estimates were 0.11 for breast cancer and 2.35 for ovarian
cancer, with corresponding odds of 2 420 000 : 1 in favour of
pathogenicity. The LR test provided some evidence for differ-
ence from a single value (X12=4.08; p=0.043) and for a differ-
ence from standard penetrance (X22=7.53; p=0.023).
For R1699Q, the maximum likelihood estimate of the pene-
trance multiplier parameter was 0.20 (95% CI 0.09 to 0.45), was
signiﬁcantly reduced compared with the standard model
(X12=14.2; p=0.0002). The odds in favour of pathogenicity were
6226 : 1 for R1699Q at this value of the multiplier, whereas, they
were only 5 : 1 under the standard model. In contrast with
R1699W, allowing separate multipliers for breast and ovarian
cancer did not result in a big difference in likelihood, with esti-
mated parameters of 0.18 for breast cancer and 0.30 for ovarian
cancer (odds of 6787:1), which was not signiﬁcantly different
from a single value of 0.20 (p=0.7) for breast and ovarian cancer.
Clearly, there is a reduced penetrance for this variant, com-
pared with the standard penetrance of BRCA1 as estimated by
Antoniou et al.17 To represent these estimated parameters in
terms of absolute risks which are perhaps more clinically
relevant, we can translate the penetrance multipliers into age-
speciﬁc relative risks of breast and ovarian cancer, and use these
to obtain cumulative risks of breast and/or ovarian cancer by
age, based on the age-speciﬁc relative risks in Antoniou et al.17
Figure 1 shows the predicted cumulative risks of developing
either breast or ovarian cancer based on the maximum likeli-
hood parameter estimates of the breast and ovarian relative risk
multiplier parameters for R1699Q and R1699W, compared with
the standard model and population rates. Similar ﬁgures for
breast cancer risk and ovarian cancer risk, individually, are pro-
vided in the supplementary ﬁgure S3. If our model is correct,
the risk of breast or ovarian cancer to age 70 is 24% (95% CI
10% to 40%) for carriers of BRCA1 R1699Q, and 58% (95% CI
7% to 72%) for carriers of BRCA1 R1699W, assuming the best
ﬁtting model of separate risk multipliers for breast and ovarian
cancers. This compares with 4.6% for women in the general
population, and 68% for the carriers of an average pathogenic
mutation. The risks for R1699Q are higher than that conferred
by family history alone, but still lower than those conferred by
BRCA2 and PALB2 mutations.
DISCUSSION
Although we have presented results of analyses examining risk,
our goal was not to estimate penetrance per se, but rather to
compare these two speciﬁc variants with the penetrance of the
‘average’ BRCA1 mutation (the vast majority of which are trun-
cating), both in terms of family histories of probands carrying
these variants and in terms of cosegregation of the variants
within families. Here we provide, for the ﬁrst time, signiﬁcant
evidence that a BRCA1 variant can be associated with reduced
risks of breast cancer compared with the ‘average’ pathogenic
mutation. It is of particular relevance and consequence for future
studies, since the variant R1699Q was selected for study due to
its behaviour in a variety of functional assays. Depending on the
assay, this missense variant has demonstrated either wild-type
function, abrogated function akin to known pathogenic muta-
tions, or functional activity intermediate between that observed
for wild-type BRCA1 and known truncating pathogenic and mis-
sense pathogenic mutations.
Figure 1 Cumulative risk of breast or ovarian cancer by age,
assuming the best ﬁtting models of penetrance for R1699Q (dotted line)
and R1699W (dashed line). The corresponding curves for the standard
penetrance (solid line) and for the general population (dash-dotted line)
are also shown.
Table 2 Analysis of family history scores
Group Number of families* Mean BOADICEA score†
Z-scores‡
Mean SE
BRCA-X 243 0.085 0.0 0.06
R1699Q 67 0.12 0.48 0.14
R1699W 34 0.36 1.81 0.20
H0: Q=0 t=3.51, 66 df, p=0.0004
H0: Q=W t=−5.5, 99 df, p=1.3×10−7
*Analysis includes 67 families in which the proband carried a R1699Q variant and for
which there was at least one matching BRCA-X family, and the 34 matching families in
which the proband had a R1699W variant. One R1699Q family was excluded because
there was no BRCA-X family available for comparison. For another R1699Q family with
only a single matched BRCA-X family, the SD could not be determined, so the average SD
across all centres was used for analysis. Families were matched by country, as shown in
table 1.
†All BOADICEA scores represent ‘pre-test’ calculations based on family history
information only. Score ranges were as follows: Q: 0.0006 to 0.88; W: 0.0026 to 0.97;
X: 0.0002 to 0.92.
‡See text for definition of Z-scores.
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Interestingly, there was also evidence that the R1699W
variant was associated with signiﬁcantly lower breast cancer
risk and a markedly increased risk of ovarian cancer. We recog-
nise that the estimation of breast and ovarian cancer parameters,
separately, is somewhat difﬁcult given the necessity of condi-
tioning the data on all pedigree phenotypes, but the results,
nevertheless, raise the question that differences in risk of breast
versus ovarian cancer may be a characteristic of some missense
mutations in the BRCT repeat domains. In this regard, we note
that in the 34 R1699W families, there were an average of 2.24
breast cancers and 1.48 ovarian cancers, while in the 68 R1699Q
families, there were 2.35 breast cancers and 0.85 ovarian cancers
per family, consistent with the higher estimated risk of ovarian
cancer in these families. Further study of a large number of such
variants will be necessary to address such an intriguing possibil-
ity that would have clear clinical implications.
Using the standard multifactorial model, the posterior prob-
ability for R1699Q is calculated to be 0.79 from the available
data, namely: prior probability of pathogenicity of 0.66 based
on the A-GVGD class C3523; segregation odds of 5:1 in favour
of pathogenicity from this study of 30 families; LRs from
Easton et al11 of 8:1 against pathogenicity for family history,
and 3:1 in favour of pathogenicity for co-occurrence data. That
is, using the model developed based on the characteristics of
BRCA1 pathogenic mutations of ‘average’ penetrance, R1699Q
would be classiﬁed as International Agency for Research on
Cancer (IARC) Class 3 ‘uncertain’.
Our conclusive ﬁnding that BRCA1 c.5096G>A R1699Q can be
shown to have both intermediate functional deﬁciency in several
assays, and is associated with breast and ovarian cancer risk at sig-
niﬁcantly lower levels than truncating BRCA1 mutations, has a
number of consequences. Our ﬁndings suggest that results from a
battery of functional assays may highlight other variants with
intermediate or equivocal results for investigation as potential
moderate risk variants. Indeed, the variant BRCA1 A1708V
showed abrogated centrosome ampliﬁcation, but normal nuclear
foci formation and trypsin sensitivity equivocal results from a
series of functional assays in our original report,8 and is a candidate
for further investigation as a potential moderate risk variant.
If this observation of intermediate function translating to
intermediate risk is a general ﬁnding, it is likely that there will
be a subset of variants that are difﬁcult to classify using the
standard multifactorial likelihood approaches that are based on
comparing data for a particular variant under the hypothesis
that it is a fully penetrant pathogenic BRCA1 mutation, against
the hypothesis that it is neutral, or of no clinical signiﬁcance,
with respect to risk. As shown for the R1699Q variant with
more families available for analysis than will likely be achieved
for most other rare variants, the standard cosegregation analysis
yielded odds of only 5:1 in favour of the variant being patho-
genic compared with the >6000:1 odds when a lower pene-
trance was allowed. Further, and more importantly, we must
now face the question of how these women should be coun-
selled in terms of cancer risk and the management of that risk.
We do not propose that counselling be any different for
R1699W, although results from the two parameter analyses
suggest that particular attention should perhaps be paid to
ovarian cancer for this known pathogenic variant. We empha-
sise, however, that the CI are wide, particularly for cancer site-
speciﬁc risks, and future studies are necessary to conﬁrm the
markedly increased ovarian cancer risk observed in our dataset.
While there is certainly signiﬁcant evidence that R1699Q car-
riers are at increased risk over population rates, this risk is
markedly lower than that observed for the average BRCA1
mutation. The ﬁndings presented here are likely to provide
impetus for research studies considering approaches to clinical
management of patients with cancer risks intermediate to
those conferred by BRCA1/2 mutations, and those from family
history alone. In the case of R1699Q, counselling could be
similar to that for other moderate-penetrance genes such as
PALB2, CHEK2 and RAD51C, although that may change if
ovarian cancer screening improves given the increased rate of
ovarian cancer over the general population. In all these cases,
the incorporation of the now 30+ common breast cancer sus-
ceptibility alleles into comprehensive risk prediction models
will be of great value in allowing women and their providers to
make informed management decisions. In addition, it would be
interesting to speciﬁcally explore if BRCA1 haplotypes altering
promoter activity,34 35 or potentially altering 30 untranslated
region (UTR) microRNA binding,36 inﬂuence the level of func-
tion of R1699Q in vivo, and explain in part the variable presen-
tation of families.
In summary, we provide evidence that a BRCA1 variant demon-
strating equivocal functional deﬁciency across multiple assays is
associated with intermediate risk of breast and ovarian cancer,
highlighting challenges for risk modelling and clinical management
of patients of this and other potential moderate-risk variants.
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